等待开盘 03-26 09:30:00 美东时间
+1.550
+2.70%
Recursion (Nasdaq: RXRX) said on Wednesday that it had named Vicki Goodman as chief medical officer, effective April 6, 2026, succeeding David Mauro. Goodman had more than two decades of experience in...
03-25 20:44
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet Rewrites throughout, adds Merck's shares in paragraph 4, adds analyst comments in paragraphs 8, 13-16 March 25 (Reuters) - Merck MRK.N said on Wednesday it would buy biotech Terns Pharma TERN.O for $6.7 billion, as the drugma
03-25 18:54
Recursion announced that Dr. Vicki Goodman will replace Dr. David Mauro as its Chief Medical Officer. Dr. Goodman brings extensive oncology and clinical development expertise, including roles at Exelixis, Merck, and Bristol Myers Squibb, and experience as an FDA reviewer. Her leadership will support Recursion's clinical pipeline and regulatory milestones. Dr. Mauro will transition out of his role after three years, with Najat Khan expressing grat...
03-25 11:59
(来源:抗体圈) 行业格局逆转:从普遍扩张到集体收缩 对比近年数据,制药行业用人策略出现根本性反转。2022 年,17 家大型药企中仅 3 家启动裁员;到...
03-24 15:34
3月23日,上海市静安区召开2026年外资外贸转型升级推进大会,推出支持外资(总部)企业转型发展能级提升8条举措(简称“静八条”),系统打造外资转型静安模式,让...
03-23 18:35
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-chemotherapy-previously-untreated-hodgkin-lymphoma
03-21 00:31
RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), am...
03-20 02:37
Bristol-Myers Squibb to report first-quarter 2026 results BMS will report first-quarter 2026 results on April 30, 2026. A conference call is scheduled for April 30, 2026 at 8:00 a.m. ET, with a live webcast at http://investor.bms.com . Disclaimer: This news brief was created by Public Technologies (
03-19 18:59
Evotec receives USD 10 million milestone payment from Bristol Myers Squibb after Phase 1 study start Bristol Myers Squibb started a Phase 1 study of BMS-986506, a CELMoD drug candidate developed under its protein degradation partnership with Evotec. Evotec will receive a milestone payment of USD 10
03-19 14:36
Evotec to receive USD 10 million milestone as BMS starts Phase 1 study of BMS-986506 Bristol Myers Squibb initiated a Phase 1 clinical study of BMS-986506 in advanced clear cell renal cell carcinoma. Evotec is set to receive a USD 10 million milestone payment tied to the study initiation. Disclaimer
03-19 14:32
公司名称
|
百时美施贵宝
|
行业分类
|
制药
|
业务描述
|
百时美施贵宝是一家以“研发并提供创新药物,帮助患者战胜严重疾病”为使命的全球性生物制药公司。公司拥有约25000名员工。2016年,百时美施贵宝全球研发投入达近50亿美元,占全年产品净销售额的28%。
|
Recursion (Nasdaq: RXRX) said on Wednesday that it had named Vicki Goodman as chief medical officer, effective April 6, 2026, succeeding David Mauro. Goodman had more than two decades of experience in...
03-25 20:44
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet Rewrites throughout, adds Merck's shares in paragraph 4, adds analyst comments in paragraphs 8, 13-16 March 25 (Reuters) - Merck MRK.N said on Wednesday it would buy biotech Terns Pharma TERN.O for $6.7 billion, as the drugma
03-25 18:54
Recursion announced that Dr. Vicki Goodman will replace Dr. David Mauro as its Chief Medical Officer. Dr. Goodman brings extensive oncology and clinical development expertise, including roles at Exelixis, Merck, and Bristol Myers Squibb, and experience as an FDA reviewer. Her leadership will support Recursion's clinical pipeline and regulatory milestones. Dr. Mauro will transition out of his role after three years, with Najat Khan expressing grat...
03-25 11:59
(来源:抗体圈) 行业格局逆转:从普遍扩张到集体收缩 对比近年数据,制药行业用人策略出现根本性反转。2022 年,17 家大型药企中仅 3 家启动裁员;到...
03-24 15:34
3月23日,上海市静安区召开2026年外资外贸转型升级推进大会,推出支持外资(总部)企业转型发展能级提升8条举措(简称“静八条”),系统打造外资转型静安模式,让...
03-23 18:35
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-chemotherapy-previously-untreated-hodgkin-lymphoma
03-21 00:31
RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), am...
03-20 02:37
Bristol-Myers Squibb to report first-quarter 2026 results BMS will report first-quarter 2026 results on April 30, 2026. A conference call is scheduled for April 30, 2026 at 8:00 a.m. ET, with a live webcast at http://investor.bms.com . Disclaimer: This news brief was created by Public Technologies (
03-19 18:59
Evotec receives USD 10 million milestone payment from Bristol Myers Squibb after Phase 1 study start Bristol Myers Squibb started a Phase 1 study of BMS-986506, a CELMoD drug candidate developed under its protein degradation partnership with Evotec. Evotec will receive a milestone payment of USD 10
03-19 14:36
Evotec to receive USD 10 million milestone as BMS starts Phase 1 study of BMS-986506 Bristol Myers Squibb initiated a Phase 1 clinical study of BMS-986506 in advanced clear cell renal cell carcinoma. Evotec is set to receive a USD 10 million milestone payment tied to the study initiation. Disclaimer
03-19 14:32
派息除权日
|
每股总股息
| 派息日期 |
2026-04-02
|
0.63
|
2026-05-01
|
2026-01-02
|
0.63
|
2026-02-02
|
2025-10-03
|
0.62
|
2025-11-03
|
2025-07-03
|
0.62
|
2025-08-01
|
2025-04-04
|
0.62
|
2025-05-01
|
2025-01-03
|
0.62
|
2025-02-03
|
2024-10-04
|
0.60
|
2024-11-01
|
2024-07-05
|
0.60
|
2024-08-01
|
2024-04-04
|
0.60
|
2024-05-01
|
2024-01-04
|
0.60
|
2024-02-01
|
2023-10-05
|
0.57
|
2023-11-01
|
2023-07-06
|
0.57
|
2023-08-01
|
2023-04-06
|
0.57
|
2023-05-01
|
2023-01-05
|
0.57
|
2023-02-01
|
2022-10-06
|
0.54
|
2022-11-01
|
2022-06-30
|
0.54
|
2022-08-01
|
2022-03-31
|
0.54
|
2022-05-02
|
2022-01-06
|
0.54
|
2022-02-01
|
2021-09-30
|
0.49
|
2021-11-01
|
2021-07-01
|
0.49
|
2021-08-02
|
2021-03-31
|
0.49
|
2021-05-03
|
2020-12-31
|
0.49
|
2021-02-01
|
2020-10-01
|
0.45
|
2020-11-02
|
2020-07-02
|
0.45
|
2020-08-03
|
2020-04-02
|
0.45
|
2020-05-01
|
2020-01-02
|
0.45
|
2020-02-03
|
2019-10-03
|
0.41
|
2019-11-01
|
2019-07-03
|
0.41
|
2019-08-01
|
2019-04-04
|
0.41
|
2019-05-01
|
2019-01-03
|
0.41
|
2019-02-01
|
2018-10-04
|
0.40
|
2018-11-01
|
2018-07-05
|
0.40
|
2018-08-01
|
2018-04-05
|
0.40
|
2018-05-01
|
2018-01-04
|
0.40
|
2018-02-01
|
2017-10-05
|
0.39
|
2017-11-01
|
2017-07-05
|
0.39
|
2017-08-01
|
2017-04-05
|
0.39
|
2017-05-01
|
2017-01-04
|
0.39
|
2017-02-01
|
2016-10-05
|
0.38
|
2016-11-01
|
2016-06-29
|
0.38
|
2016-08-01
|
2016-03-30
|
0.38
|
2016-05-02
|
2015-12-30
|
0.38
|
2016-02-01
|
2015-09-30
|
0.37
|
2015-11-02
|
2015-07-01
|
0.37
|
2015-08-03
|
2015-04-01
|
0.37
|
2015-05-01
|
2014-12-30
|
0.37
|
2015-02-02
|
2014-10-01
|
0.36
|
2014-11-03
|
2014-07-01
|
0.36
|
2014-08-01
|
2014-04-02
|
0.36
|
2014-05-01
|
2013-12-31
|
0.36
|
2014-02-03
|
2013-10-02
|
0.35
|
2013-11-01
|
2013-07-02
|
0.35
|
2013-08-01
|
2013-04-03
|
0.35
|
2013-05-01
|
2013-01-02
|
0.35
|
2013-02-01
|
2012-10-03
|
0.34
|
2012-11-01
|
2012-07-03
|
0.34
|
2012-08-01
|
2012-04-03
|
0.34
|
2012-05-01
|
2012-01-04
|
0.34
|
2012-02-01
|
2011-10-06
|
0.33
|
2011-11-01
|
2011-06-29
|
0.33
|
2011-08-01
|
2011-03-30
|
0.33
|
2011-05-02
|
2011-01-05
|
0.33
|
2011-02-01
|
2010-09-29
|
0.32
|
2010-11-01
|
2010-06-30
|
0.32
|
2010-08-02
|
2010-03-30
|
0.32
|
2010-05-03
|
2009-12-30
|
0.32
|
2010-02-01
|
2009-09-30
|
0.31
|
2009-11-02
|
2009-07-01
|
0.31
|
2009-08-03
|
2009-04-01
|
0.31
|
2009-05-01
|
2008-12-30
|
0.31
|
2009-02-02
|
2008-10-01
|
0.31
|
2008-11-03
|
2008-07-02
|
0.31
|
2008-08-01
|
2008-04-02
|
0.31
|
2008-05-01
|
2008-01-02
|
0.31
|
2008-02-01
|
2007-10-03
|
0.28
|
2007-11-01
|
2007-07-03
|
0.28
|
2007-08-01
|
2007-04-03
|
0.28
|
2007-05-01
|
2007-01-03
|
0.28
|
2007-02-01
|
2006-10-04
|
0.28
|
2006-11-01
|
2006-07-05
|
0.28
|
2006-08-01
|
2006-04-05
|
0.28
|
2006-05-01
|
2006-01-04
|
0.28
|
2006-02-01
|
2005-10-05
|
0.28
|
2005-11-01
|
2005-06-29
|
0.28
|
2005-08-01
|
2005-03-30
|
0.28
|
2005-05-02
|
2005-01-05
|
0.28
|
2005-02-01
|
2004-09-29
|
0.28
|
2004-11-01
|
2004-06-30
|
0.28
|
2004-08-02
|
2004-03-31
|
0.28
|
2004-05-03
|
2003-12-30
|
0.28
|
2004-02-02
|
2003-10-01
|
0.28
|
2003-11-03
|
2003-07-01
|
0.28
|
2003-08-01
|
2003-04-02
|
0.28
|
2003-05-01
|
2002-12-31
|
0.28
|
2003-02-01
|
2002-10-02
|
0.28
|
2002-11-01
|
2002-07-02
|
0.28
|
2002-08-01
|
2002-04-03
|
0.28
|
2002-05-01
|
2002-01-02
|
0.28
|
2002-02-01
|
2001-10-03
|
0.28
|
2001-11-01
|
2001-07-03
|
0.28
|
2001-08-01
|
2001-04-04
|
0.28
|
2001-05-01
|
2001-01-03
|
0.28
|
2001-02-01
|
2000-10-04
|
0.25
|
2000-11-01
|
2000-07-05
|
0.25
|
2000-08-01
|
2000-04-05
|
0.25
|
2000-05-01
|
2000-01-05
|
0.25
|
2000-02-01
|
1999-09-29
|
0.22
|
1999-11-01
|
1999-06-30
|
0.22
|
1999-08-01
|
1999-03-30
|
0.22
|
1999-05-01
|
1999-01-06
|
0.43
|
1999-02-01
|
1998-09-30
|
0.39
|
1998-11-01
|
1998-06-30
|
0.39
|
1998-08-01
|
1998-04-01
|
0.39
|
1998-05-01
|
1997-12-30
|
0.39
|
1998-02-01
|
1997-10-01
|
0.38
|
1997-11-01
|
1997-07-01
|
0.38
|
1997-08-01
|
1997-04-02
|
0.38
|
1997-05-01
|
1996-12-31
|
0.76
|
1997-02-01
|
1996-10-02
|
0.75
|
1996-11-01
|
1996-07-02
|
0.75
|
1996-08-01
|
1996-04-02
|
0.75
|
1996-05-01
|
1996-01-03
|
0.75
|
1996-02-01
|
1995-10-04
|
0.74
|
1995-11-01
|
1995-07-05
|
0.74
|
1995-08-01
|
1995-04-03
|
0.74
|
1995-05-01
|
1994-12-30
|
0.74
|
1995-02-01
|
1994-10-03
|
0.73
|
1994-11-01
|
1994-06-27
|
0.73
|
1994-08-01
|
1994-03-25
|
0.73
|
1994-05-01
|
1994-01-03
|
0.73
|
1994-02-01
|
1993-09-27
|
0.72
|
1993-11-01
|
1993-06-28
|
0.72
|
1993-08-01
|
1993-03-29
|
0.72
|
1993-05-01
|
1993-01-04
|
0.72
|
1993-02-01
|
1992-09-28
|
0.69
|
1992-11-01
|
1992-06-26
|
0.69
|
1992-08-01
|
1992-03-30
|
0.69
|
1992-05-01
|
1991-12-27
|
0.69
|
1992-02-01
|
1991-09-30
|
0.60
|
1991-11-01
|
1991-06-28
|
0.60
|
1991-08-01
|
1991-04-01
|
0.60
|
1991-05-01
|
1990-12-28
|
0.60
|
1991-02-01
|
1990-10-01
|
0.53
|
1990-11-01
|
1990-06-29
|
0.53
|
1990-08-01
|
1990-04-02
|
0.53
|
1990-05-01
|
1989-12-29
|
0.53
|
1990-02-01
|
1989-09-19
|
0.50
|
1989-11-01
|
1989-06-30
|
0.50
|
1989-08-01
|
1989-04-03
|
0.50
|
1989-05-01
|
1988-12-30
|
0.50
|
1989-02-01
|
1988-10-03
|
0.42
|
1988-11-01
|
1988-06-27
|
0.42
|
1988-08-01
|
1988-03-25
|
0.42
|
1988-05-01
|
1988-01-04
|
0.42
|
1988-02-01
|
1987-09-28
|
0.35
|
1987-11-01
|
1987-06-26
|
0.35
|
1987-08-01
|
1987-03-30
|
0.70
|
1987-05-01
|
1986-12-26
|
0.70
|
1987-02-01
|
1986-09-29
|
0.55
|
1986-11-01
|
1986-06-27
|
0.55
|
1986-08-01
|
1986-03-31
|
0.55
|
1986-05-01
|
1985-12-07
|
0.47
|
1986-02-01
|
1985-09-30
|
0.47
|
1985-11-01
|
1985-06-08
|
0.47
|
1985-08-01
|
1985-03-09
|
0.47
|
1985-05-01
|
1984-12-08
|
0.40
|
1985-02-01
|
1984-10-01
|
0.40
|
1984-11-01
|
1984-06-29
|
0.40
|
1984-08-01
|
1984-04-02
|
0.40
|
1984-05-01
|
1983-12-30
|
0.30
|
1984-02-01
|
1983-10-03
|
0.30
|
1983-11-01
|
1983-07-01
|
0.30
|
1983-08-01
|
1983-01-03
|
0.52
|
1983-02-01
|
1982-10-04
|
0.52
|
1982-11-01
|
1982-07-02
|
0.52
|
1982-08-01
|
1982-04-04
|
0.60
|
1982-05-01
|
1982-04-02
|
0.52
|
1982-05-01
|
1982-01-04
|
0.46
|
1982-02-01
|
1981-10-05
|
0.46
|
1981-11-01
|
1981-07-06
|
0.46
|
1981-08-01
|
1981-04-06
|
0.46
|
1981-05-01
|
1981-01-05
|
0.40
|
1981-02-01
|
1980-10-06
|
0.40
|
1980-11-01
|
1980-06-30
|
0.40
|
1980-08-01
|
1980-03-27
|
0.40
|
1980-05-01
|
1979-12-27
|
0.36
|
1980-01-31
|
1979-10-04
|
0.36
|
1979-10-31
|
1979-06-28
|
0.36
|
1979-07-31
|
1979-04-01
|
0.36
|
1979-04-30
|
1978-12-28
|
0.31
|
1979-01-31
|
1978-10-01
|
0.31
|
1978-10-31
|
1978-06-29
|
0.31
|
1978-07-31
|
1978-03-30
|
0.31
|
1978-04-30
|
1977-12-29
|
0.28
|
1978-01-31
|
1977-10-02
|
0.28
|
1977-10-31
|
1977-06-26
|
0.28
|
1977-07-31
|
